IDDI's Added Value:

  • Experience in  Oncology - Ophthalmology - Infectious diseases - Cardiovascular diseases.
  • Expertise in methodology and specific study designs and analyses.
  • Efficient web systems (ID-net™, ID-supply™,  ID-code™, TrialControl™).
  • Scientific  publications and presentations (350+ publications and 400+ presentations).
  • Dedicated team of talented professionals with extensive scientific depth.
  • Trial results that are scientifically accurate, validated and reproducible.
  • Stability and independent status, 20 years in the clinical trials business.
  • Regulatory experience with involvement in 14 approvals.
  • Worldwide reputation and scientific visibility.

Success Stories demonstrate how the methodology and web systems of IDDI are key in the conduct of the clinical trials.

300 trials (Phase I-IV) over the last 5 years

 

>> FREE LIVE WEBINAR

FRIDAY SEPTEMBER 3, 2010


 DEVELOPMENT AND VALIDATION OF CLINICALLY USEFUL GENE SIGNATURES

Join Marc Buyse of IDDI and Stefan Michiels of Institut Bordet.

Friday September 3, 2010

04:00 PM CET - 10:00 AM  EST - 7:00 AM  PST

REGISTER HERE   

 

Past Webinar :